Lymphedema | NYU Langone Health
NYU Langone doctors are experts in managing lymphedema, a buildup of fluid that causes swelling in arms, legs, hands, and feet.
M20-638: A PHASE 3 MULTICENTER RANDOMIZED OPEN-LABEL TRIAL OF EPCORITAMAB IN COMBINATION WITH RITUXIMAB AND LENALIDOMIDE (R2) COMPARED TO RITUXIMAB AND LENALIDOMIDE (R2) ALONE IN SUBJECTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
This is a trial testing a new medicine called epcoritamab, when used with other medicines called rituximab and lenalidomide (together called "R2"), to see if it has few side effects and works well for patients with follicular lymphoma who have already tried other treatments (one anti-CD20 containing treatment) before. The study will have three groups of patients who will get different treatments. Everyone will be watched closely, and they will have special scans at different times in the study to see how they're doing. The doctors will look at the results after a certain number of patients have good or bad outcomes. There will be a secondary group of experts who will make sure everything is safe during the trial. The study team will take blood samples to learn more about the treatment and hope to see results that the medicine has helped patients.
Macular Degeneration | NYU Langone Health
NYU Langone specialists offer treatments for macular degeneration, a potentially serious eye condition that can cause vision loss.
Magnet Recognition Program Site Visit | NYU Langone Health
NYU Langone Health is making public notice of a Magnet Recognition Program Site Visit.
Magnetic Resonance Imaging Evaluation of Normal Heart Function in Men and Women
The purpose of the proposed study is the creation of an initial functional atlas of the normal adult human heart, using data derived with cardiac MRI. MRI can provide high-quality 2D cross-sectional cine images of the heart, in arbitrary planes, which can be placed in spatial registration with each other relative to the reference frame of the imaging system. MRI can also acquire cine images with magnetization tags, which noninvasively create fiducial markers that can be used to track material points within the heart wall; these data can be combined to reconstruct the 3D motion pattern within the heart wall. A third capability of MRI is the acquisition of images of the velocity vectors of the moving blood within the heart and great vessels. We will use MRI to acquire such functional data on a stratified sample of ~100 subjects without heart disease, distributed over the ages of 20-89, and composed of roughly equal numbers of men and women. The racial/ethnic composition of the sample will reflect our urban population; from whom we will be recruiting the subjects; there will be a range of body sizes. The data for each subject will be mutually registered, and then used to create a model of the heart wall and the motion within both the heart wall and the cavity that captures both the overall average values for motion and its variance, and the associated systematic variation with sex, age, and body size. We hypothesize that the use of the data derived for these subjects, using these MRI methods with associated analysis tools, will enable us to define an initial set of normative values for regional cardiac function variables (a “cardiac function atlas”). We expect that this, in turn, will enable us to begin to explore the associated changes in regional cardiac function found in heart disease, and to assess the potential utility of this information for diagnostic, therapeutic, and prognostic applications.
MAGNITUDE: A Phase 3 Multinational Multicenter Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
This trial is recruiting patients with a condition known as Transthyretin (TTR) Amyloidosis with Cardiomyopathy or ATTR-CM. In individuals with this condition, the heart muscle does not pump blood through the body as it should, due to build-up of abnormal protein between the muscle fibers in the heart. The specific protein is called transthyretin amyloid (TTR). Intellia Therapeutics, Inc. has developed an investigational drug called NTLA-2001. NTLA-2001 consists of a CRISPR/Cas9 gene editing system, which can “knockout” the TTR gene. This means NTLA-2001 permanently changes the DNA so the gene stops making the TTR protein. Because most of the TTR protein in the body is made in the liver, NTLA-2001 is packaged within lipid nanoparticles which are able to deliver NTLA-2001 directly into the liver and thereby avoid most of the other organs and tissues. NTLA-2001 is given intravenously (IV) (through a small flexible tube inserted into a vein in the arm or hand) slowly over about 4 hours. An individual's amyloidosis symptoms may not change, may stop worsening, or perhaps could improve as a result. By using the CRISPR/Cas 9 technology, NTLA-2001 will disable the TTR gene, but this does not involve the insertion of any permanent genetic material into the body.
Male Breast Cancer | NYU Langone Health
Perlmutter Cancer Center doctors use surgery, radiation therapy, and medication to manage male breast cancer.
Male Infertility | NYU Langone Health
NYU Langone urologists and fertility specialists are experts in managing male infertility.
Male Urinary Dysfunction | NYU Langone Health
NYU Langone urologists are experts in treating urinary dysfunction in men.
Malignant Mesothelioma | NYU Langone Health
Perlmutter Cancer Center doctors diagnose and manage malignant mesothelioma, a cancer that most often affects the lining of the lungs.